Buy Paras Healthcare; target of Rs 900: Choice Institutional Equities

Key Investment Pillars

• Specialty mix driving high-value growth: PARASHLT's focus on six core specialties (CONGO-R) accounts for ~75% of revenue, supporting sustainable growth and stronger clinical depth.
• First-mover advantage in underserved markets: The company's early entry into North India markets has established brand recognition, specialized infrastructure, and physician referral networks, providing a competitive advantage.
• Operating leverage driving accelerating growth: Rising occupancy, hospital maturation, and capacity expansion are projected to improve capacity utilization, cost absorption, and EBITDA margin.

Thesis Validation Checklist

To validate the investment thesis, investors should monitor the following signals over the next ~12 months:

• Improving occupancy rates and revenue growth
• Increasing contribution from complex procedures and specialized services
• Successful ramp-up of new hospitals and expansion into adjacent markets
• Disciplined capital allocation and balance-sheet management
• Sustained improvement in EBITDA margin and profitability The company's ability to execute on its growth strategy, maintain its clinical leadership, and navigate regulatory and competitive risks will be crucial in determining its long-term success.